Maximizing the EU Approval Tracker

Do you need to compare existing and emerging competitor products approved in the European Union? Do you want to find out which products were approved in your field of interest? With *Cortellis Regulatory Intelligence* you can quickly locate a list of EU centralized products compiled into a single Excel table.

1. On the Cortellis Regulatory home page click **Intelligence Reports** and scroll down to **Product Approval Information.**





2. Expand **Drug Submission and Approval Overview** and click on **European Union**.

3. The **Abstract** under the **Summary** provides information on the scope of the document, when it was last updated and more.



4. To open the **Excel version** of the document for easy sorting and filtering, click “Download Excel” or click **Document**, then the **Toggle Side Bar icon** in the upper left hand corner of the PDF. Next click the **Paperclip icon** that appears to open the attached Excel spreadsheet.



5. In the Excel table you'll find the products categorized by Product Name, Therapeutic Area, Product and Review Type, Registration Status and Dates, Company and other information, such as Rapporteur/Co-Rapporteur Names and Countries. Sort and Filter the table as desired.

	A	B	C	D	E	F	G	H	
1	Link to Product Approval Document	Active Ingredient(s)	Name	Application Number	Therapeutic Area	Indication(s)	Dosage Forn	Route of Administration	Pharmaceu
2	321589	quadrivalent influenza vaccine (recombinant, prepared in cell culture	SUPEMTEK	EMEA/H/C/005159	Infections	- SUPEMTEK is indicated for active immunization for the prevention of influenza disease in adults. - SUPEMTEK should be used in accordance with official	Solution	Intramuscular	One dose (0. haemaggluti strains: A/XX A/XXXXXX (H micrograms
3	321586	dapagliflozin	EDISTRIDE	EMEA/H/C/004161 Rev 14	Endocrine disorders	- EDISTRIDE is indicated in adults for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise - as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal	Tablet	Oral	5 mg; 10 mg
	321585	nivolumab	OPDIVO	EMEA/H/C/003985 Rev.33	Cancer	- OPDIVO is indicated for: - Melanoma: - OPDIVO as monotherapy or in combination with ipilimumab is	Solution	Intravenous	10 mg/ml

6. Click on the **Link to Product Approval Document** (column A) for direct access to the initial EPAR version and revisions.



For more information contact Customer Service at **LS Product Support.**